Recently published research from Business Monitor International, "Iran Pharmaceuticals & Healthcare Report Q2 2014", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 04/11/2014 -- BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market in US dollar terms to contract sharply. On a positive note, improved international relations have reduced the political risk associated with operating in the market for multinational drugmakers.
Headline Expenditure Projections
- Pharmaceuticals: IRR69,997bn (US$5.26bn) in 2013 to IRR72,591bn (US$2.42mn) in 2014; +3.7% in local currency terms and -54.0% in US dollar terms.
- Healthcare: IRR559,532bn (US$27.29bn) in 2013 to IRR694,961bn (US$28.14bn) in 2014; +24.2% in local currency terms and +3.1% in US dollar terms.
Risk/Reward Rating: Iran's business environment received a substantially higher appraisal in Q214, with a score of 41.1 out of 100. The country rose seven places in the regional rankings to 15th out of 30 countries in the Middle East and Africa region in Q214 compared with 22nd in the previous quarter. The reappraisal puts the country back to the mid-table position that it held during 2013. Its overall score of 41.1 is broadly on a par with the regional average of 42.3. Generally speaking, Iran benefits from a large and growing population and relatively widespread access to healthcare services. However, its regulatory regime - including intellectual property (IP) rights, political and economic situation - is highly questionable. Consequently, the country performs above the regional average for potential rewards and below the regional average in terms of risk.
View Full Report Details and Table of Contents
Key Trends And Developments
- In December 2013 the Tehran Times reported that several multinational drugmakers were considering investments in Iran following a thaw in relations over the country's nuclear program. German pharmaceutical major Merck is considering partnering an Iranian drugmaker to manufacture drugs in the country. French drugmaker Sanofi, and German technology and service giant Bosch are also assessing whether to tap into pharmaceutical production opportunities in Iran according to the report.
- Drugs imports in Iran increased by 40% month-on-month (m-o-m) to 1,540 tonnes, valued at US$119mn, in the eighth Iranian calendar month ended November 22. The country has allocated US$400mn for the drug imports, according to Nasser Riahi, chairman of the Syndicate of Iranian Pharmaceutical Importers. Around 97% of Iran's required drugs are currently produced domestically, of which 50% of the raw materials are imported, Iranian Health Ministry official Hossein Ayati said.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Bangladesh Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Kazakhstan Pharmaceuticals & Healthcare Report Q2 2014
- Lebanon Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014